Optimizing the identification of risk‐relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families

The introduction of multigene panel testing for hereditary breast/ovarian cancer screening has greatly improved efficiency, speed, and costs. However, its clinical utility is still debated, mostly due to the lack of conclusive evidences on the impact of newly discovered genetic variants on cancer ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppa, Anna, Nicolussi, Arianna, D'Inzeo, Sonia, Capalbo, Carlo, Belardinilli, Francesca, Colicchia, Valeria, Petroni, Marialaura, Zani, Massimo, Ferraro, Sergio, Rinaldi, Christian, Buffone, Amelia, Bartolazzi, Armando, Screpanti, Isabella, Ottini, Laura, Giannini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773970/
https://www.ncbi.nlm.nih.gov/pubmed/29271107
http://dx.doi.org/10.1002/cam4.1251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773970/
https://www.ncbi.nlm.nih.gov/pubmed/29271107
http://dx.doi.org/10.1002/cam4.1251

Ejemplares similares